The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.


Goker B. , Biray A.

Cytokine & growth factor reviews, vol.54, pp.51-61, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 54
  • Publication Date: 2020
  • Doi Number: 10.1016/j.cytogfr.2020.06.013
  • Title of Journal : Cytokine & growth factor reviews
  • Page Numbers: pp.51-61
  • Keywords: SARS-CoV-2, COVID-19, JAK/STAT pathway, Ruxolitinib, Cytokine storm, REACTIVATION, SARS-COV-2, INFECTION, PATIENT, CORONAVIRUS, CYTOKINES

Abstract

Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway.